The secondary research process involved comprehensive analysis of regulatory databases, international standards bodies, peer-reviewed clinical journals, medical device industry associations, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) 510(k) and PMA databases, European Medicines Agency (EMA) and Notified Bodies under Medical Device Regulation (MDR 2017/745) and In Vitro Diagnostic Regulation (IVDR 2017/746), International Organization for Standardization (ISO) 13485 and ISO 14971 standards, International Electrotechnical Commission (IEC) 60601 series, Advanced Medical Technology Association (AdvaMed), MedTech Europe, Health Canada Medical Devices Bureau, Pharmaceuticals and Medical Devices Agency (PMDA Japan), National Medical Products Administration (NMPA China), Therapeutic Goods Administration (TGA Australia), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI/PubMed), Centers for Disease Control and Prevention (CDC) National Health Statistics, World Health Organization (WHO) Medical Device Policy and Global Health Observatory, OECD Health Statistics, World Bank Health, Nutrition and Population Statistics, EU Eurostat Healthcare Data, and national health ministry reports from key markets including China NHC, India CDSCO, and Brazil ANVISA.
Medical device approval data, regulatory pathway analysis, procedure volumes, hospital equipment procurement statistics, reimbursement codes, clinical safety studies, and market landscaping for diagnostic imaging systems, surgical robotics, patient monitoring devices, cardiovascular implants, and orthopedic prosthetics were gathered from these sources.